Exelixis
EXEL
#1697
Rank
ยฃ7.90 B
Marketcap
ยฃ27.66
Share price
0.52%
Change (1 day)
63.53%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of September 2024 : ยฃ2.35 Billion

According to Exelixis's latest financial reports the company's total assets are ยฃ2.35 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2023-12-31ยฃ2.30 B-9.03%
2022-12-31ยฃ2.53 B30.99%
2021-12-31ยฃ1.93 B23.61%
2020-12-31ยฃ1.56 B9.04%
2019-12-31ยฃ1.43 B28.34%
2018-12-31ยฃ1.12 B131.09%
2017-12-31ยฃ0.48 B0.43%
2016-12-31ยฃ0.48 B115.29%
2015-12-31ยฃ0.22 B8.01%
2014-12-31ยฃ0.20 B-31.95%
2013-12-31ยฃ0.30 B-31.61%
2012-12-31ยฃ0.44 B76.33%
2011-12-31ยฃ0.25 B8.26%
2010-12-31ยฃ0.23 B10.13%
2009-12-31ยฃ0.21 B-22.56%
2008-12-31ยฃ0.27 B32.1%
2007-12-31ยฃ0.20 B2.76%
2006-12-31ยฃ0.20 B4.63%
2005-12-31ยฃ0.19 B27.14%
2004-12-31ยฃ0.15 B-24.13%
2003-12-31ยฃ0.20 B-5.43%
2002-12-31ยฃ0.21 B-11.53%
2001-12-31ยฃ0.23 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
ยฃ61.70 B 2,524.37%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ110.47 B 4,598.71%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ93.34 B 3,870.30%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ74.39 B 3,064.23%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ72.18 B 2,970.08%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ141.60 B 5,922.64%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ174.31 B 7,314.03%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ40.04 M-98.30%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ80.4 M-96.58%๐Ÿ‡บ๐Ÿ‡ธ USA